Navigation Links
XL Advantage Prismatic

ProductsXL Advantage Prismatic
Company Keeler Instruments Inc.
Item XL Advantage Prismatic
Features 
  • Keeler Prismatic loupes offer magnifications of 3.5x, 4.5x and 5.5x in 3 working distances
  • Superb Quality
  • Laser Aligned Optics
  • 4 Working Distances
  • Available with Keeler Frames and K-LED
  • High Magnification
  • Anti Reflective Coating
  • Available on Headband
    • Description Keeler Prismatic loupes are higher magnification with prismatic optics, guarenteeing edge to edge clarity and precise colour rendition.

    Keeler Prismatic loupes are laser aligned and treated with anti reflective coating to produce a superior image.

    Info Keeler Instruments Inc.
    Customer Service: (800) 523-5620
    Web site: http://www.keelerusa.com

    Related medicine products :

    1. XL Advantage 3.5x @ 34cm working distance
    2. XL Advantage 3.5x @ 46cm working distance
    3. XL Advantage 4.5x @ 34cm working distance
    4. XL Advantage 4.5x @ 42cm working distance
    5. XL Advantage 4.5x @ 46cm working distance
    6. XL Advantage 5.5x @ 34cm working distance
    7. XL Advantage 5.5x @ 42cm working distance
    8. XL Advantage 5.5x @ 46cm working distance
    9. MultiWash Advantage
    10. XL Advantage
    11. The Global Advantage Shoulder System
    Lorenz 2.0 mm titanium system for the midface provides an excellent alternative to lower profile systems in areas of the midface where greater fixation is needed.
    The Neuroclip is designed for safe, quick, and stable fixation of cranial bone flaps. Application is simple with minimal instrumentation. The Neuroclip can be applied to the cranial bone flap while t
    Lorenz 1.0 mm titanium system provides a rigid fixation alternative for areas with high palpability and prominent bone formation. These areas include the frontal bone and the areas surrounding the or
    1.0 mm Micro System. The Titanium Micro System is also useful in the practice of ENT, Neurosurgery and Handsurgery.
    Medicine Products:
    (Date:10/7/2008)...RNewswire-FirstCall/ -- Stallergenes S.A.,today an...greement with,Catalent for the promotion and distr...FLEX(R), co-developed and co-manufactured by Catal...sts of a syringe pre-filled with adrenaline, which....3 and 0.15 mg), in an,autoinjector device. The Me...
    (Date:10/7/2008)...of asthma in a young child may well be more challe..., according to a review of research and clinical e... Indiana University School of Medicine and Riley H... issue of Clinical Pediatrics . , "Wheezing ca... Professor of Pediatrics at the IU School of Medic...
    (Date:10/7/2008)...rial Specialties, Mfg. is pleased to announce the ...hese filters are exclusively available from Indust... push-to-connect style fittings integrated into th...ne filter offers versatility and customization for... (PRWEB) October 7, 2008 -- Exclusively availa...
    (Date:10/6/2008)...fight against childhood obesity, researcher notes ... Three-quarters of middle schools have vending mac...new study finds. , The research demonstrates th...ls, and "that those vending machines don,t always ...y Virus, a registered dietitian with the Center fo...
    Breaking Medicine News(10 mins):Health News:Stallergenes Partners With Catalent and the Medical House for Commercialization of Adrenaline Autoinjector in Europe 2Health News:Wheezing and asthma in young children 2Health News:Vending Machines Found in Most Middle Schools 2
    India, Pakistan Teams To Inaugurate Inzy's Hospital
    ... been found through an animal study that Aspartame...ut that drinking four to five 20-ounce bottles of ...be the //cause of cancers. The study would be pub...ironmental Health Perspectives, an US government-r...
    ...East Asia has been long considered a wonderland fo...otel lobbies or restaurants without any inhibition...vernment is seriously thinking about imposing a sm...bars. In Malaysia and Thailand, smoking bans alre...
    ...attempting to learn a new task, taking short break...easy, according to a new study conducted by Massac...d Foster and Matthew Wilson, working at the Massac...bridge, found that rats' brains 'replay' their exp...
    Other Medicine News:Health News:Smoking Ban To Be Soon Implemented In South East Asian Bars 2Health News:Task Learning Made Simple By Taking Short Breaks 2
    (Date:10/6/2008)...G, Pa., Oct. 6 /- Genaera,C...om its second Phase 1,clinical trial of trodusquem...the treatment of type 2 diabetes and obesity. MSI-...lecular target that controls the function,of both ...se and decrease,appetite. In the study, MSI-1436 w...
    (Date:10/6/2008)...erence Call Scheduled for 9:00 AM ET Today -, SEA...rporation (Nasdaq:,DNDN) announced today that it h...hase 3, randomized, double-blind, placebo-controll...ma Treatment, also known as D9902B),clinical trial...,investigational active cellular immunotherapy PRO...
    (Date:10/6/2008)... /- Dendreon Corporation (N...nday, October 6, 2008 at 9:00 AM,ET (6:00 AM PT) t...s IMPACT,(IMmunotherapy for Prostate AdenoCarcinom...of PROVENGE(R) (sipuleucel-T), the Company,s inves...reatment of advanced prostate,cancer., Those i...
    (Date:10/5/2008)...ed in New England Journal of Medicine reaffirm,wel...e of SPIRIVA(R),HandiHaler(R), RIDGEFIELD, Conn.,...he,UPLIFT (Understanding Potential Long-term Impac... SPIRIVA(R) HandiHaler(R) (tiotropium bromide,inha...ction for up to 4,years as measured by FEV(1) (p<0...
    Breaking Medicine Technology:Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting 2Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting 3Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting 4Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial 2Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial 3Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial 4Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial 2Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years 2Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years 3Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years 4Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years 5Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years 6RoundTable Healthcare Partners Closes Sale of MedAssist Holding Inc to Firstsource Solutions Limited 939 1RoundTable Healthcare Partners Closes Sale of MedAssist Holding Inc to Firstsource Solutions Limited 939 2RoundTable Healthcare Partners Closes Sale of MedAssist Holding Inc to Firstsource Solutions Limited 939 3Center for Poverty Research to study senior hunger in America 2387 1Center for Poverty Research to study senior hunger in America 2387 2Connecticut Catholic Conference Wrong to Allow Plan B in Catholic Hospitals 2384 1Connecticut Catholic Conference Wrong to Allow Plan B in Catholic Hospitals 2384 2American Academy of Dermatology Association Commends President Bush for Signing Tanning Accountability and Notification 28TAN 29 Act 2380 1American Academy of Dermatology Association Commends President Bush for Signing Tanning Accountability and Notification 28TAN 29 Act 2380 2
    ...e/ -- A nationally renowned,cancer researcher affi...nted a novel study design concept called a Complet...e new agent development.,Studies utilizing this de...work,s innovative Translational Oncology Program (...e trials in a community,setting. These types of tr...
    ...nted at American Society of,Clinical Oncology (ASC...Newswire-FirstCall/ -- Medarex, Inc.,and Bristol-M...ultiple clinical studies of ipilimumab (MDX-010), ...h advanced melanoma.,The results demonstrated an a...melanoma either as a monotherapy or in combination...
    Other Medicine Technology:Study Shows Advantages of Complete Phase Ib Trial Over Separate,Phase I Trials 2Study Shows Advantages of Complete Phase Ib Trial Over Separate,Phase I Trials 3Study Shows Advantages of Complete Phase Ib Trial Over Separate,Phase I Trials 4Study Shows Advantages of Complete Phase Ib Trial Over Separate,Phase I Trials 5Data Demonstrated Metastatic Melanoma Response to Investigational,Immunotherapy Ipilimumab 2Data Demonstrated Metastatic Melanoma Response to Investigational,Immunotherapy Ipilimumab 3Data Demonstrated Metastatic Melanoma Response to Investigational,Immunotherapy Ipilimumab 4Data Demonstrated Metastatic Melanoma Response to Investigational,Immunotherapy Ipilimumab 5Data Demonstrated Metastatic Melanoma Response to Investigational,Immunotherapy Ipilimumab 6Data Demonstrated Metastatic Melanoma Response to Investigational,Immunotherapy Ipilimumab 7